Drugs / 611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06639295 | Nov 2024 → Dec 2025 overdue | chronic rhinosinusitis, nasal cavity polyp | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06639295 ↗ |
| Route | Subcutaneous | “611 subcutaneous (SC) injection.” NCT06639295 ↗ |